Abstract 19610: Safety of Percutaneous Left Atrial Appendage Suture Ligation: Results From the Largest Us Registry
Background: Epicardial ligation of left atrial appendage (LAA) is an attractive alternative to oral anticoagulation for patients with atrial fibrillation and high risk of bleeding.
Objectives: To delineate the safety of epicardial ligation of the LAA for stroke prevention in atrial fibrillation
Methods: This is a retrospective, multicenter registry of consecutive patients undergoing LAA ligation with the LARIAT device at 14 U.S. sites. The primary endpoint was procedural success, defined as device success (suture deployment and <5 mm leak by post-procedure transesophageal echocardiography), and no major complication at discharge (death, myocardial infarction, stroke, major bleeding requiring transfusion, or cardiac perforation requiring cardiac surgery).
Results: A total of 610 patients underwent LARIAT exclusion of LAA. The mean age of the participants was 71 (SD: ± 10) years. The mean CHADs2VASc and HASBLED score was 2.74(±1.33) and 3.87 (±1.8) respectively. Epicardial access was obtained using micro-puncture needle in 60 percent of the cases. The acute closure was achieved in 554 (91 %) patients. Cardiac perforation needing continued drainage and transfusion occurred in 12 patients (1.96 %). Perforation of epigastric artery occurred in 2 patients (0.3 %). Eight patients (1.3 %) required open heart surgery. Five patients required > 2 weeks of treatment for pericarditis. No myocardial infarction or stroke happened in the peri-procedural period. One patient died as complication of the procedure. A follow up transesophageal echocardiogram (TEE) was performed in 76 % of the patients that showed a leak of < 5 mm and thrombus in 49 (8 %) and 12 (1.96 %) patients respectively.
Conclusions: In this largest multicenter experience of LAA ligation with the LARIAT device, the rate of acute closure was high with significantly fewer complications compared to limited contemporary data. The use of micro-puncture is probably safer approach to avoid cardiac injury during epicardial access. A prospective randomized trial is required to adequately define clinical efficacy, optimal post-procedure medical therapy, and the effect of operator experience on procedural safety.
Author Disclosures: D. Lakkireddy: Other; Modest; DL has received honorariums from SentreHEART, Inc.. S. Gunda: None. M.R. Afzal: None. M. Reddy: None. R.J. Lee: None. J. Nath: None. H. Nagaraj: None. C. Ellis: None. E. Altman: None. B. Lee: None. D. Wilber: None. S. Kar: None. R. Ferrell: None. S. Bommana: None. D. Atkins: None. N. Bhadwar: None. M. Sanchez: None. V. Gadiyaram: None. D. Tschopp: None. R. Evonich: None. A. Rasekh: None. J. Cheng: None. D. Gibson: None. E. Matthew: None.
- © 2015 by American Heart Association, Inc.